应用Meta分析法系统地评估了生脉注射液（SMI）联合常规疗法治疗急性心肌梗死（AMI）的疗效及安全性。检索7个数据库，纳入SMI结合常规治疗与单独常规治疗比较对AMI患者治疗效果的随机对照试验（RCT）。根据Cochrane标准分别进行文献筛选、数据提取和质量评估，数据分析使用RevMan软件（V.5.3）。18个文献的RCTs（包括1 258名患者）被纳入评价系统。与常规治疗相比，在其基础上加用SMI可降低死亡率及心律失常、心源性休克、心力衰竭发生率，改善左心室射血分数（LVEF）、每搏输出量（SV）和冠状动脉再通率。对照组和治疗组均可发生轻度出血、心悸、呼吸短促、疲劳等不良反应。纳入研究样本量少且质量较低，所得结论尚需低偏倚风险和足够样本量的高质量RCT予以证实。

This Meta-analysis systematically assessed the efficacy and safety of Shengmai Injection (SMI) combined with conventional treatment for acute myocardial infarction (AMI). Seven online databases were investigated, then randomized clinical trials (RCTs) of treatment effects of AMI patients, for which SMI was used in combination with conventional therapy compared with conventional therapy alone, were included. The literatures selection, data extraction, and quality assessment were in accordance with the Cochrane standards. Data analysis was carried out using RevMan software (V.5.3). RCTs (enrolling 1 258 patients) from 18 literatures published in Chinese journals were included in the systermatic review. The additional SMI could significantly reduce the risk of mortality, arrhythmia, cardiogenic shock, heart failure and improve left ventricular ejection fraction (LVEF), stroke volume (SV), vascular patency rate. The adverse effects of mild bleeding, palpitation, shortness of breath, fatigue could occur both in the control group and the treatment group. Thus, it was difficult to evaluate the safety of SMI due to the limited data and low-guality RCTs. Therefore, high-quality and adequate sample of RCTs with low risk of bias are required to demonstrate its true effects.

国家自然科学基金面上项目（81574044）